Novanta Inc. — Q1 2021 Form 10-Q
Business context and period. Novanta supplies photonics, vision and precision-motion technologies to medical and advanced-industrial OEMs. The unaudited quarter ended April 2, 2021; comparisons are with the quarter ended April 3, 2020. Amounts below are U.S. dollars unless stated otherwise.
Financial performance
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | $162.6m | $155.5m | +4.6% |
| Gross profit / margin | $68.7m / 42.3% | $64.4m / 41.5% | Margin +0.8 percentage points |
| Operating income / margin | $11.1m / 6.8% | $13.3m / 8.5% | Income −16.2% |
| Net income | $11.3m | $11.9m | −5.3% |
| Diluted EPS | $0.32 | $0.34 | −$0.02 |
| Operating cash flow | $23.3m | $17.8m | +$5.5m |
Revenue growth reflected stronger advanced-industrial demand, particularly in microelectronics and manufacturing, partly offset by weaker medical demand amid deferred elective procedures. Foreign exchange added $5.4m, or 3.5%, to revenue. Operating income fell as higher R&D and restructuring/acquisition costs offset higher gross profit. The effective tax rate was negative 20.8%, including a substantial tax benefit from vesting share-based awards; this helped offset the operating-income decline.
Segments
- Photonics: revenue $58.5m (+6.1%); operating income $12.4m versus $8.9m. Gross margin rose to 48.1% from 44.7%, mainly on higher factory utilization.
- Vision: revenue $67.6m (−2.0%); operating income $3.4m versus $5.6m. Medical minimally invasive surgery demand remained affected by procedure deferrals.
- Precision Motion: revenue $36.5m (+16.4%); operating income $7.4m versus $6.5m. Gross margin was 44.1%, compared with 44.4%.
Medical represented approximately 55% of revenue, down from 58%; advanced industrial represented 45%, up from 42%.
Financial position and liquidity
- Cash and cash equivalents were $113.6m at April 2, 2021, down from $125.1m at year-end 2020. Current assets were $309.1m and current liabilities $117.4m.
- Senior credit facility borrowings were approximately $196.5m principal ($99.2m term loan and $96.3m revolver); reported debt carrying value was $191.4m after debt issuance costs. The revolving facility had $398.7m of unused availability and matures in December 2024.
- Cash provided by operations was $23.3m; investing used $5.5m and financing used $28.9m. Financing outflows included $18.3m of payroll taxes on vested share awards and $8.7m to purchase a building previously under finance lease.
- Capital expenditures were $3.3m in the quarter. Management expects approximately $21m–$23m for fiscal 2021.
- The company reported compliance with its debt covenants: leverage ratio 1.35 versus a maximum 3.50; fixed-charge coverage ratio 10.95 versus a minimum 1.50.
Outlook, risks and unusual items
- No specific full-year revenue or earnings guidance is provided. Management stated it expects operating cash flows to cover operating and capital needs for at least the next 12 months.
- The 2020 restructuring program is expected to be substantially complete in Q4 2021; Novanta expects another $6m–$7m of related charges over the next 12 months. Q1 restructuring, acquisition and related costs were $3.7m, including restructuring and legal costs connected to an acquired business.
- COVID-19 continues to create demand uncertainty and has contributed to elective-procedure deferrals. Management also cited component shortages, supply-chain and transportation delays, and higher raw-material, freight, packaging and energy costs. The company has generally offset cost increases through productivity measures and some customer price increases, but may not recover all increases promptly.
- An arbitration demand against a business acquired in 2019 alleges breach of a joint product-development agreement and seeks damages and other relief. Novanta considers the claims without merit and recorded no accrual; the ultimate outcome is uncertain.
- Management reported no material changes to the risk factors in its 2020 Form 10-K, and concluded disclosure controls were effective as of April 2, 2021.
Important facts for investors to verify
- Whether advanced-industrial growth continues and medical demand recovers as elective procedures resume.
- Whether segment and consolidated margins withstand higher input, freight and COVID-related costs, and increased R&D and restructuring spending.
- The timing and cash impact of the additional restructuring charges, fiscal 2021 capital spending, and debt repayment.
- The sustainability of the unusually favorable effective tax rate, including the impact of share-award tax benefits.
- Developments in the acquired-business arbitration and any resulting financial exposure.